Kanafani Zeina A, Perfect John R
American University of Beirut Medical Center, Beirut, Lebanon.
Clin Infect Dis. 2008 Jan 1;46(1):120-8. doi: 10.1086/524071.
Despite advances in preventive, diagnostic, and therapeutic interventions, invasive fungal infections cause significant morbidity and mortality in immunocompromised patients. The burden of antifungal resistance in such high-risk patients is becoming a major concern. A better understanding of the mechanisms and clinical impact of antifungal resistance is essential to the prompt and efficient treatment of patients with invasive mycoses and to improving the outcome of such infections. Although recent guidelines have attempted to standardize antifungal susceptibility testing, limitations still exist as a result of the incomplete correlation between in vitro susceptibility and clinical response to treatment. Four major mechanisms of resistance to azoles have been identified, all of which rely on altered gene expression. Mechanisms responsible for polyene and echinocandin resistance are less well understood. In addition to discussing the molecular mechanisms of antifungal resistance, this article elaborates on the concept of clinical resistance, which is critical to the understanding of treatment failure in patients with invasive fungal infections.
尽管在预防、诊断和治疗干预方面取得了进展,但侵袭性真菌感染在免疫功能低下的患者中仍会导致显著的发病率和死亡率。此类高危患者中抗真菌耐药性的负担正成为一个主要问题。更好地了解抗真菌耐药性的机制和临床影响对于及时有效地治疗侵袭性真菌病患者以及改善此类感染的治疗结果至关重要。尽管最近的指南试图规范抗真菌药敏试验,但由于体外药敏与临床治疗反应之间的相关性不完全,仍然存在局限性。已确定了四种主要的唑类耐药机制,所有这些机制都依赖于基因表达的改变。对多烯类和棘白菌素类耐药的机制了解较少。除了讨论抗真菌耐药性的分子机制外,本文还阐述了临床耐药性的概念,这对于理解侵袭性真菌感染患者的治疗失败至关重要。